Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Blog Article

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma.We provide one additional year BOSCH Serie 6 BFL554MS0B Built-in Solo Microwave - Stainless Steel of follow up and include the effect on minimal residual disease and in clinically relevant subgroups.After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs.17.

5 months; hazard ratio, 0.41; 95% confidence Iron interval, 0.31-0.53; P.